Author:
Zakumumpa Henry,Alinaitwe Adolf,Kyomuhendo Marjorie,Nakazibwe Brenda
Funder
Consortium for Advanced Research Training in Africa
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Phillips AN, Bansi-Matharu L, Cambiano V, Ehrenkranz P, Serenata C, Venter F, Pett S, Flexner C, Jahn A, Revill P, Garnett GP. The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-saharan Africa: a modelling analysis. Lancet Global Health. 2021;9(5):e620–7.
2. Kanazawa JT, Saberi P, Sauceda JA, Dubé K. The LAIs are coming! Implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a scoping review. AIDS Res Hum Retroviruses. 2021;37(2):75–88.
3. Izudi J, Cattamanchi A, Castelnuovo B, King R. Barriers and facilitators to viral load suppression among people living with HIV following intensive adherence counseling in Kampala, Uganda: a qualitative study. Soc Sci Med. 2024;343:116595.
4. UNAIDS. 2022. Delays in global, affordable access to long-acting, injectable HIV medicines would cost lives, say AIDS campaigners.https://www.unaids.org/en/resources/presscentre/featurestories/2022/november/20221116_long-acting-injectable-HIV-medicines
5. Dawood H. The optimum implementation of long-acting injectable cabotegravir–rilpivirine in sub-saharan Africa. Lancet Global Health. 2021;9(5):e563–4.